Company Long-Term Loans and Borrowings: genfit.com (GNFT)

Public company logo of GENFIT (GNFT)

This chart illustrates that the market value of Genfit S.A. (GNFT) on the GURU.Markets platform is 0.00, which correlates with the commercial launch of Iqirvo and progress in liver failure therapy. The business relies on patent protection, allowing the company to generate massive profits with minimal drug production costs. The company's strategy is based on establishing R&D alliances with global leaders rather than pursuing mergers.

GNFT Genfit SA Company Long-Term Debts (07/04/2022 - 12/06/2025)

Summary analytical data breakdowns for GENFIT (GNFT)

- market price and analyst price targets:
Stock Price Genfit SA|GNFT - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Genfit S.A.|GNFT - Total Company Value
- book capitalization information:
Accounting Value per Share Genfit S.A.|GNFT - Book Capitalization|Market Capitalization to Book Value Ratio genfit.com|GNFT - Cumulative Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Genfit S.A.|GNFT - Long-Term Debt to Equity|Short-Term Debt to Equity Genfit SA|GNFT - Company Aggregate Debts|Debts to Net Assets Genfit S.A.|GNFT - Company Long-Term Liabilities|Company Short-Term Debt Genfit S.A.|Immediate Liquidity genfit.com
- earnings and multiples data:
GNFT - Company Net Income
Summary company analytics:GNFT Genfit S.A.
Brand item of Genfit SA

Long-term debt determines the financial stability of an issuer by measuring the total volume of obligations with a maturity exceeding one year. This metric assesses a company's ability to service loans without the risk of bankruptcy. By analyzing the long-term debt chart of a business, an investor can track the dynamics of the credit load. For Genfit S.A. (GNFT), such loans are critical for financing costly R&D research in hepatology until the commercialization of patents.

Competitor analysis for Genfit S.A.

Company Long-Term Debts arrowheadpharma.com ARWR|MIRM - Company Long-Term Debt|Company Long-Term Loans and Borrowings DVAX (dynavax.com)|Arbutus (ABUS) - Company Long-Term Debt|Company Long-Term Liabilities Inventiva Corp|GYRE (Gyre Therapeutics, Inc.) - Company Long-Term Debts|Company Long-Term Debts assemblybio.com|Company Long-Term Liabilities GALT (Galectin Therapeutics)|DRRX (durect.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Aligos Therapeutics, Inc. ALGS|BioVie Inc - Company Long-Term Debt|Galmed Pharma - Company Long-Term Debts|Long-Term Debt Volume endrainc.com NDRA|HEPA (hepionpharma.com) - Company Long-Term Liabilities